 |
|
|
| |
TURQUOISE-II: Trends in Liver Fibrosis Testing, Hepatic Synthetic Function, and Platelet Counts at Baseline and 12 Weeks After Treatment With ABT-450/r/Ombitasvir and Dasabuvir With Ribavirin in HCV Genotype 1-Infected Patients With Cirrhosis
|
| |
| |
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Mitchell L Shiffman1, Kris V Kowdley2, Fred Poordad3, Stefan Zeuzem4, David Muti mer5, Marc Bourlière6, Thomas Berg7, Samuel S Lee8, Sandra Lovell9, Leticia Canizaro9, Roger Trinh9, Guy Neff 9, Paul Kwo10
1Liver Institute of Virginia, Bon Secours Health System, Newport News, Virginia, United States; 2Swedish Medical Center, Seattle, Washington, United States; 3The Texas Liver Insti tute, University of Texas Health Science Center, San Antonio, Texas, United States; 4JW Goethe University, Frankfurt, Germany;
5Queen Elizabeth Hospital and NIHR Liver Biomedical Research Unit, Birmingham, United Kingdom; 6Hôpital Saint Joseph, Marseille, France; 7Universitätsklinikum Leipzig, Leipzig, Germany; 8University of Calgary, Calgary, Alberta, Canada; 9AbbVie Inc., North Chicago, Illinois, United States;
10Indiana University, Indianapolis, Indiana, United States
EASL: TURQUOISE-II: SVR12 RATE OF 92-96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/r/ABT-267 AND ABT-333 PLUS RIBAVIRIN - (04/14/14)
|
| |
|
|
|
|
|
